EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms

Raanan Greenman iD, Chris J Weston iD

Cells · 2025-01-13 · 14 (2) · 105

DOI: 10.3390/cells14020105 ↗

At a glance

Übersichtsarbeit in Cells, published online on 2025-01-13. Written by Raanan Greenman and 1 co-authors. Institution: Chemomab Therapeutics Ltd., Tel Aviv 6158002, Israel. Major MEDLINE topics: Fibrosis, Chemokine CCL24. Cited 13 times so far (Crossref); 162 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Tissue fibrosis results from a dysregulated and chronic wound healing response accompanied by chronic inflammation and angiogenesis. Regardless of the affected organ, fibrosis shares the following common hallmarks: the recruitment of immune cells, fibroblast activation/proliferation, and excessive extracellular matrix deposition. Chemokines play a pivotal role in initiating and advancing these fibrotic processes. CCL24 (eotaxin-2) is a chemokine secreted by immune cells and epithelial cells, which promotes the trafficking of immune cells and the activation of profibrotic cells through CCR3 receptor binding. Higher levels of CCL24 and CCR3 were found in the tissue and sera of patients with fibro-inflammatory diseases, including primary sclerosing cholangitis (PSC), systemic sclerosis (SSc), and metabolic dysfunction-associated steatohepatitis (MASH). This review delves into the intricate role of CCL24 in fibrotic diseases, highlighting its impact on fibrotic, immune, and vascular pathways. We focus on the preclinical and clinical evidence supporting the therapeutic potential of blocking CCL24 in diseases that involve excessive inflammation and fibrosis.

Subjects

MeSH terms (MEDLINE)

FibrosisChemokine CCL24HumansAnimalsInflammation

Author keywords

CCL24CCR3chemokineeotaxin-2fibrosismetabolic dysfunction-associated steatohepatitisprimary sclerosing cholangitissystemic sclerosis

Substances

Chemokine CCL24

Authors and institutions

  • Chemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.
  • Department of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK.
  • National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, Birmingham B15 2TT, UK.

ORCID profiles: Raanan Greenman, Chris J Weston

Funding

  • National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC)

Cite

APA

Greenman, R., & Weston, C. J. (2025). CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms. Cells, 14(2), 105. https://doi.org/10.3390/cells14020105

Vancouver

Greenman R, Weston CJ. CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms. Cells. 2025;14(2):105. doi:10.3390/cells14020105

BibTeX
@article{Greenman2025,
  author = {Greenman, Raanan and Weston, Chris J},
  title = {CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {2},
  pages = {105},
  doi = {10.3390/cells14020105}
}
Start for free →